To initiate and evaluate a multilevel navigation intervention to promote lung cancer screening among Black/African Americans

Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades despite numerous attempts to augment standard therapies. Multi-targeted receptor tyrosine kinase inhibitors (MTKIs), such as cabozantinib, can target signaling pathways that are known to be altered in osteosarcoma. Several MTKIs including cabozantinib have recently shown clinical evidence of activity in prospective studies for both pediatric and adult patients with advanced osteosarcoma. Furthermore, feasibility of administering MTKIs in combination with cytotoxic chemotherapy has previously been shown in patients with AML, hepatocellular carcinoma, and soft tissue sarcomas. Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades

The purpose of this study is to to determine the efficacy (as measured by Neurocognitive testing) of oral memantine administered for a period of 6 months, when compared to placebo, in children ages 4-18 receiving cranial or craniospinal radiotherapy for primary central nervous system tumors.

To see if women who had breast cancer at ages 18-40 were able to successfully lactate and breastfeed after lumpectomy and radiation treatment afterwards.

We have created this registry to provide an opportunity to study diagnostic capabilities, administration protocols and long-term effects of contrast-enhanced ultrasound (CEUS) of any organ.

This study seeks to promote clinical trial engagement in African Americans with pancreatic cancer. The first group of people will be interviewed by phone to discuss clinical trials. This information will be used to create a new mobile health app/website. In the second group, half of the participants will receive the new app and half will not. They will both be asked to complete questionnaires after their upcoming doctor visits.

This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.

Some female cancers may be genetic, meaning they are passed down from a parent through DNA (our genetic code or roadmap). In people with certain types of ovarian and uterine cancer, it may be helpful to test their DNA for any errors that can cause cancer. There are lots of important pieces of information to share when someone is diagnosed with cancer, and we are exploring a new way to share information. Patients with certain types of ovarian or uterine cancers will watch a short video that explains what genetic testing is and why it is so important. They will fill out a survey about what they think about the video and if the information is helpful.

The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

We are implementing a digital health intervention, mPATH-Cloud, in one community health center. Patients who receive a link to the mPATH-Cloud website will be able to view a video designed to help them choose the colorectal cancer (CRC) screening test that is best for them. Patients who select colonoscopy will receive a referral from their primary care provider. Patients who do not select colonoscopy will receive a FIT in the mail. We will assess the feasibility and effectiveness of implementing mPATH-Cloud in combination with mailed FIT outreach for increasing CRC screening among community health center patients.